Glucose-functionalized gold nanoparticles as a metabolically targeted CT contrast agent for distinguishing tumors from non-malignant metabolically active processes

Tamar Dreifuss; Menachem Motiei; Oshra Betzer; Aron Popovtzer; Galith Abourbeh; Eyal Mishani; Rachela Popovtzer

doi:10.1117/12.2249850

Glucose-functionalized gold nanoparticles as a metabolically targeted CT contrast agent for distinguishing tumors from non-malignant metabolically active processes

Tamar Dreifuss, Menachem Motiei, Oshra Betzer, Aron Popovtzer, Galith Abourbeh, Eyal Mishani, Rachela Popovtzer

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

2 Scopus citations

Abstract

The highly used cancer imaging technique, [¹⁸F]FDG-PET, is based on the increased glucose metabolic activity in tumors. However, since there are other biological processes that exhibit increased metabolic activity, in particular inflammation, this methodology is prone to non-specificity for cancer. Herein we describe the development of a novel nanoparticle-based approach, utilizes Glucose-Functionalized Gold Nanoparticles (GF-GNPs) as a metabolically targeted CT contrast agent. Our method has demonstrated specific tumor targeting and has successfully differentiated between cancer and inflammation in a combined tumor-inflammation mouse model, due to dissimilarities in vasculatures in different pathologic conditions. This novel approach provides new capabilities in cancer imaging, and can be applicable to a wide range of cancers.

Original language	English
Title of host publication	Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV
Editors	Dan V. Nicolau, Dror Fixler, Alexander N. Cartwright
Publisher	SPIE
ISBN (Electronic)	9781510605954
DOIs	https://doi.org/10.1117/12.2249850
State	Published - 2017
Event	Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV 2017 - San Francisco, United States Duration: 30 Jan 2017 → 1 Feb 2017

Publication series

Name	Progress in Biomedical Optics and Imaging - Proceedings of SPIE
Volume	10077
ISSN (Print)	1605-7422

Conference

Conference	Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV 2017
Country/Territory	United States
City	San Francisco
Period	30/01/17 → 1/02/17

Bibliographical note

Publisher Copyright:
© 2017 SPIE.

Funding

This work was partially supported by the Research and Development Chief Scientist Kamin grant (49544), by the Israel Cancer Research Fund (ICRF), by the Israel Science Foundation grant (749/14), and by the doctoral scholarship for applicable and scientific engineering research, granted to Tamar Dreifuss and Oshra Betzer by the Ministry of Science, Technology & Space, Israel.

Funders	Funder number
Research and Development Chief Scientist Kamin	49544
Israel Cancer Research Fund
Ministry of Science, Technology and Space
Israel Science Foundation	749/14

Keywords

CT
Cancer
FDG-PET
Gold nanoparticles
Metabolic-based imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1117/12.2249850

Cite this

Dreifuss, T., Motiei, M., Betzer, O., Popovtzer, A., Abourbeh, G., Mishani, E., & Popovtzer, R. (2017). Glucose-functionalized gold nanoparticles as a metabolically targeted CT contrast agent for distinguishing tumors from non-malignant metabolically active processes. In D. V. Nicolau, D. Fixler, & A. N. Cartwright (Eds.), Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV Article 100770I (Progress in Biomedical Optics and Imaging - Proceedings of SPIE; Vol. 10077). SPIE. https://doi.org/10.1117/12.2249850

Dreifuss, Tamar ; Motiei, Menachem ; Betzer, Oshra et al. / Glucose-functionalized gold nanoparticles as a metabolically targeted CT contrast agent for distinguishing tumors from non-malignant metabolically active processes. Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV. editor / Dan V. Nicolau ; Dror Fixler ; Alexander N. Cartwright. SPIE, 2017. (Progress in Biomedical Optics and Imaging - Proceedings of SPIE).

@inproceedings{5f984ca05b664a83a80938c9aa06632f,

title = "Glucose-functionalized gold nanoparticles as a metabolically targeted CT contrast agent for distinguishing tumors from non-malignant metabolically active processes",

abstract = "The highly used cancer imaging technique, [18F]FDG-PET, is based on the increased glucose metabolic activity in tumors. However, since there are other biological processes that exhibit increased metabolic activity, in particular inflammation, this methodology is prone to non-specificity for cancer. Herein we describe the development of a novel nanoparticle-based approach, utilizes Glucose-Functionalized Gold Nanoparticles (GF-GNPs) as a metabolically targeted CT contrast agent. Our method has demonstrated specific tumor targeting and has successfully differentiated between cancer and inflammation in a combined tumor-inflammation mouse model, due to dissimilarities in vasculatures in different pathologic conditions. This novel approach provides new capabilities in cancer imaging, and can be applicable to a wide range of cancers.",

keywords = "CT, Cancer, FDG-PET, Gold nanoparticles, Metabolic-based imaging",

author = "Tamar Dreifuss and Menachem Motiei and Oshra Betzer and Aron Popovtzer and Galith Abourbeh and Eyal Mishani and Rachela Popovtzer",

note = "Publisher Copyright: {\textcopyright} 2017 SPIE.; Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV 2017 ; Conference date: 30-01-2017 Through 01-02-2017",

year = "2017",

doi = "10.1117/12.2249850",

language = "אנגלית",

series = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",

publisher = "SPIE",

editor = "Nicolau, {Dan V.} and Dror Fixler and Cartwright, {Alexander N.}",

booktitle = "Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV",

address = "ארצות הברית",

}

Dreifuss, T, Motiei, M, Betzer, O, Popovtzer, A, Abourbeh, G, Mishani, E & Popovtzer, R 2017, Glucose-functionalized gold nanoparticles as a metabolically targeted CT contrast agent for distinguishing tumors from non-malignant metabolically active processes. in DV Nicolau, D Fixler & AN Cartwright (eds), Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV., 100770I, Progress in Biomedical Optics and Imaging - Proceedings of SPIE, vol. 10077, SPIE, Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV 2017, San Francisco, United States, 30/01/17. https://doi.org/10.1117/12.2249850

Glucose-functionalized gold nanoparticles as a metabolically targeted CT contrast agent for distinguishing tumors from non-malignant metabolically active processes. / Dreifuss, Tamar; Motiei, Menachem; Betzer, Oshra et al.
Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV. ed. / Dan V. Nicolau; Dror Fixler; Alexander N. Cartwright. SPIE, 2017. 100770I (Progress in Biomedical Optics and Imaging - Proceedings of SPIE; Vol. 10077).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

TY - GEN

T1 - Glucose-functionalized gold nanoparticles as a metabolically targeted CT contrast agent for distinguishing tumors from non-malignant metabolically active processes

AU - Dreifuss, Tamar

AU - Motiei, Menachem

AU - Betzer, Oshra

AU - Popovtzer, Aron

AU - Abourbeh, Galith

AU - Mishani, Eyal

AU - Popovtzer, Rachela

PY - 2017

Y1 - 2017

N2 - The highly used cancer imaging technique, [18F]FDG-PET, is based on the increased glucose metabolic activity in tumors. However, since there are other biological processes that exhibit increased metabolic activity, in particular inflammation, this methodology is prone to non-specificity for cancer. Herein we describe the development of a novel nanoparticle-based approach, utilizes Glucose-Functionalized Gold Nanoparticles (GF-GNPs) as a metabolically targeted CT contrast agent. Our method has demonstrated specific tumor targeting and has successfully differentiated between cancer and inflammation in a combined tumor-inflammation mouse model, due to dissimilarities in vasculatures in different pathologic conditions. This novel approach provides new capabilities in cancer imaging, and can be applicable to a wide range of cancers.

AB - The highly used cancer imaging technique, [18F]FDG-PET, is based on the increased glucose metabolic activity in tumors. However, since there are other biological processes that exhibit increased metabolic activity, in particular inflammation, this methodology is prone to non-specificity for cancer. Herein we describe the development of a novel nanoparticle-based approach, utilizes Glucose-Functionalized Gold Nanoparticles (GF-GNPs) as a metabolically targeted CT contrast agent. Our method has demonstrated specific tumor targeting and has successfully differentiated between cancer and inflammation in a combined tumor-inflammation mouse model, due to dissimilarities in vasculatures in different pathologic conditions. This novel approach provides new capabilities in cancer imaging, and can be applicable to a wide range of cancers.

KW - CT

KW - Cancer

KW - FDG-PET

KW - Gold nanoparticles

KW - Metabolic-based imaging

UR - http://www.scopus.com/inward/record.url?scp=85020300746&partnerID=8YFLogxK

U2 - 10.1117/12.2249850

DO - 10.1117/12.2249850

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.conference???

AN - SCOPUS:85020300746

T3 - Progress in Biomedical Optics and Imaging - Proceedings of SPIE

BT - Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV

A2 - Nicolau, Dan V.

A2 - Fixler, Dror

A2 - Cartwright, Alexander N.

PB - SPIE

T2 - Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV 2017

Y2 - 30 January 2017 through 1 February 2017

ER -

Dreifuss T, Motiei M, Betzer O, Popovtzer A, Abourbeh G, Mishani E et al. Glucose-functionalized gold nanoparticles as a metabolically targeted CT contrast agent for distinguishing tumors from non-malignant metabolically active processes. In Nicolau DV, Fixler D, Cartwright AN, editors, Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV. SPIE. 2017. 100770I. (Progress in Biomedical Optics and Imaging - Proceedings of SPIE). doi: 10.1117/12.2249850

Glucose-functionalized gold nanoparticles as a metabolically targeted CT contrast agent for distinguishing tumors from non-malignant metabolically active processes

Abstract

Publication series

Conference

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this